Cerus Corporation (NASDAQ:CERS) is highlighted as one of the Best Get Rich Fast Stocks to Buy Right Now, with TD Cowen viewing its Intercept Fibrinogen Complex franchise as an “underappreciated” growth engine. The firm believes the BCA partnership will enhance adoption, scalability, and profitability in the U.S. blood center space, maintaining a ‘Buy’ rating with a price target of $5, reflecting a potential upside of 143%.

On December 10, Cerus Corporation (NASDAQ:CERS) announced a purchasing agreement with Blood Centers of America (BCA) to incorporate its INTERCEPT product offering, including pathogen reduction technology. The venture aims to enhance awareness and adoption of pathogen reduction technologies, providing access to pathogen-reduced platelets for new customers, as stated by the COO.

Founded in 1991, Cerus Corporation (NASDAQ:CERS) is a California-based biomedical products company specializing in the INTERCEPT Blood System. The company offers platelet and plasma systems through a direct sales force and distributors. While the potential investment in CERS is acknowledged, certain AI stocks may offer greater upside potential and less downside risk, according to analysts.

Read more at Yahoo Finance: TD Cowen Sees Compelling Long-Term Value in Cerus Corporation (CERS)